Growth Metrics

Novartis Ag (NVS) Short term Debt (2016 - 2025)

Novartis Ag's Short term Debt history spans 11 years, with the latest figure at $794.0 million for Q4 2025.

  • On a quarterly basis, Short term Debt rose 23.68% to $794.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $794.0 million, a 23.68% increase, with the full-year FY2025 number at $794.0 million, up 23.68% from a year prior.
  • Short term Debt hit $794.0 million in Q4 2025 for Novartis Ag, up from $642.0 million in the prior quarter.
  • Over the last five years, Short term Debt for NVS hit a ceiling of $6.3 billion in Q4 2021 and a floor of $624.0 million in Q4 2023.
  • Historically, Short term Debt has averaged $2.9 billion across 5 years, with a median of $794.0 million in 2025.
  • Biggest five-year swings in Short term Debt: skyrocketed 177.07% in 2021 and later plummeted 89.48% in 2023.
  • Tracing NVS's Short term Debt over 5 years: stood at $6.3 billion in 2021, then decreased by 5.78% to $5.9 billion in 2022, then plummeted by 89.48% to $624.0 million in 2023, then grew by 2.88% to $642.0 million in 2024, then increased by 23.68% to $794.0 million in 2025.
  • Business Quant data shows Short term Debt for NVS at $794.0 million in Q4 2025, $642.0 million in Q4 2024, and $624.0 million in Q4 2023.